However, despite early findings that tumor volume and high-grade tumor volume are key indicators for biochemical recurrence of HSPC patients following initial radical prostatectomy and the routinely use of high-volume tumor assessment to guide systemic therapy decisions, the critical role of PSMA-PET tumor volume within this disease stage has long been not at the center of interest, only to regain importance at the CRPC stage 18-20. This evidence concerns the gene FOLH1 and neoplasm.